|
ABC-07 |
Addition of stereotactic radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers |
Dr Thankamma Ajithkumar |
31 Aug 2023 |
5 Apr 2017 |
Liver & Bile Duct |
|
ACELARATE |
A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patients with metastatic pancreatic carcinoma |
Dr Pippa Corrie |
14 Mar 2019 |
14 Mar 2016 |
Pancreatic |
|
ACTICCA-1 |
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer |
Dr Pippa Corrie |
1 Apr 2019 |
22 Jun 2016 |
Pancreatic |
|
Add-Aspirin Trial - Breast |
A phase III, double blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours |
Dr Luke Hughes-Davies |
11 Dec 2020 |
21 Dec 2015 |
Breast, Colorectal, Oesophageal, Prostate |
|
ADSCaN |
A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-small Cell Lung Cancer |
Dr Susan Harden |
31 Dec 2021 |
23 Nov 2017 |
Lung |
|
ALF Research Study |
Research into Altered Lymphocyte Function in Health and Disease |
Dr Kate Fife |
31 Dec 2022 |
9 Nov 2017 |
Skin & melanoma |
|
ALTAR |
Alternatives to Prophylactic Antibiotics for the Treatment of Recurrent Urinary Tract Infection in Women |
Dr Nikesh Thiruchelvam |
31 Jul 2018 |
23 Jun 2016 |
Bladder |
|
AML18 |
A Trial for Older Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome |
Dr Jenny Craig |
31 Dec 2019 |
7 Dec 2015 |
Haematological |
|
AML19 |
Adults with acute myeloid leukaemia or high-risk myelodysplastic syndrome |
Dr Jenny Craig |
9 Nov 2019 |
15 Oct 2015 |
Haematological |
|
Artist 1 |
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen |
Dr Pippa Corrie |
30 May 2018 |
21 Jul 2017 |
Pancreatic |
|
BMS Retrospective RCC Study |
Estimating health outcomes in patients with advanced or Metastatic Renal Cell Carcinoma (mRCC) treated with systemic therapy, using real-world data - CA209671 |
Dr Kate Fife |
30 Jul 2021 |
22 Mar 2017 |
Kidney |
|
CA017-055 Nivolumab and BMS-986205 in melanoma |
A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated. |
Dr Pippa Corrie |
27 Nov 2022 |
24 Jan 2018 |
Skin & melanoma |
|
Cambridge Prostate Biopsy Device: CAMPROBE |
Developing a safer and more accurate device for biopsies of suspected cancer |
Mr Vincent Gnanapragasam |
30 Sep 2019 |
2 Feb 2016 |
Prostate |
|
CANC - 4687 Javelin Ovarian 200 B9991009 |
A phase 3, multicenter, randomized, open-label study of avelumab (msb0010718c) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer |
Dr Christine Parkinson |
30 Sep 2019 |
29 Sep 2016 |
Gynaecological |
|
CANC 30404 (KEYNOTE 427) |
A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Advanced Renal Cell Carcinoma (MK-3475-427) |
Dr Kate Fife |
30 Apr 2018 |
23 Feb 2017 |
Kidney |
|
CO39303 |
A phase III, randomised, double-blind, placebo-controlled, multicenter trial testing Ipatasertib plus abiraterone plus Prednisone/Prednisolone, relative to placebo plus Abirateron plus Prednisone/Prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer |
Dr Simon Pacey |
31 Dec 2018 |
9 Nov 2017 |
Prostate |
|
CR UK Stratified Medicine Pilot study |
The Cancer Research UK Stratified Medicine Programme: Pilot Study |
Professor VP Collings |
31 Dec 2018 |
27 Jul 2011 |
Lung |
|
EMBRACE-II |
Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer |
Dr Li Tee Tan |
30 Jun 2024 |
7 Nov 2017 |
Gynaecological |
|
ENZARAD |
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer |
Dr Yvonne Rimmer |
1 Jan 2028 |
17 Apr 2016 |
Prostate |
|
EPOCH |
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy |
Dr Charles Wilson |
31 Oct 2019 |
26 Jul 2017 |
Colorectal, Kidney |
|
ESPAC-4 |
EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers |
Dr Pippa Corrie |
28 Jan 2019 |
24 Jun 2009 |
Pancreatic |
|
Euro Ewing 2012 |
International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours |
Dr Denise Williams |
31 May 2019 |
30 Apr 2015 |
Sarcoma |
|
FACT Study |
Factors associated with Childhood Tumours Study |
Dr Amos Burke |
31 Dec 2018 |
10 Aug 2006 |
Brain and CNS, Child & Leukaemia, Gynaecological, Sarcoma, Skin & melanoma |
|
FAST-Forward |
FAST Forward is a randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in patients with early breast cancer.
The lymphatic RT sub-study an extension to the FAST-Forward trial, which maintains its original design but whose entry is now restricted to patients prescribed radiotherapy to level I-III axilla and/or level IV axilla (supraclavicular fossa (SCF)) in addition to the breast/chest wall area.
|
Dr Charlotte Coles |
1 Feb 2022 |
12 Mar 2012 |
Breast |
|
FLAIR |
Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab |
Dr George Follows |
4 Feb 2019 |
19 Jan 2015 |
Haematological |
|
FOCUS 4 |
FOCUS4 – Molecular selection of therapy in colorectal cancer: a molecularly stratified randomised controlled trials programme |
Dr Hugo Ford |
25 Nov 2020 |
1 Dec 2015 |
Colorectal |
|
HALO (CANC - 4997) |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Cancer |
Dr Pippa Corrie |
31 Mar 2019 |
16 Nov 2016 |
Pancreatic |
|
HGUSStudy |
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment |
Dr Helen Hatcher |
30 Jun 2018 |
11 Mar 2016 |
Sarcoma |
|
HIPPO |
A randomized phase II trial of Hippocampal Sparing versus Conventional Whole Brain Radiotherapy after surgical section or radiosurgery in favourable prognosis patients with 1-4 brain metastases |
Dr Sarah Jefferies |
31 Dec 2018 |
10 Nov 2016 |
Brain and CNS |
|
ICON8B |
A phase III randomised trial investigating the combination of dose-fractionated chemotherapy & bevacizumab compared to either strategy alone for the first line treatment of women with newly diagnosed high risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer |
Dr Helena Earl |
31 Jul 2019 |
8 Feb 2012 |
Gynaecological |
|
Incyte INCB54828-202 |
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy |
Dr Bristi Basu |
31 Dec 2018 |
13 Jul 2017 |
Liver & Bile Duct |
|
INTERIM |
a randomised phase II feasibility study of INTERmittent versus continuous dosing of oral targeted combination therapy In patients with BRAFV600 mutant stage 3 unresectable or metastatic Melanoma |
Dr Pippa Corrie |
30 Apr 2019 |
3 Nov 2017 |
Skin & melanoma |
|
IoN |
IoN Is ablative radio-iodine necessary for low risk differentiated thyroid cancer patients |
Dr Sarah Jefferies |
31 Dec 2019 |
28 Nov 2012 |
Head & neck |
|
LI-1 |
Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI1) Trial |
Dr Pramila Krishnamurthy |
31 Dec 2019 |
17 Feb 2014 |
Haematological |
|
LOGS |
A randomised phase II/II study to assess the efficacy of Trametinib (GSK 1120212) in patients with recurrent of progressive low grade serous ovarian cancer or peritoneal cancer |
Dr Helena Earl |
28 Feb 2020 |
11 Mar 2016 |
Gynaecological |
|
MDS Registry for newly diagnosed patients |
A prospective, multicentre European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes |
Professor Alan Warren |
1 May 2020 |
16 Feb 2009 |
Haematological |
|
MDV3800-06 |
A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone) |
Dr Danish Mazhar |
30 Apr 2018 |
18 Oct 2017 |
Prostate |
|
MelResist |
Investigating resistance to gene-targeted melanoma therapies |
Dr Pippa Corrie |
31 Dec 2018 |
3 Dec 2011 |
Skin & melanoma |
|
Minitub Registration Study (EORTC 1208) |
Prospective registry of Sentinel Node (SN) positive melanoma patients with minimal SN tumor burden who undergo Completion Lymph Node Dissection (CLND) or Nodal Observation |
Dr Amer Durrani |
1 May 2021 |
19 Oct 2017 |
Skin & melanoma |
|
MISSION: GliomaS |
A physiological exploratory study to assess tissue structure and metabolism in Glioma using sodium-23 Magnetic Resonance Imaging (23Na-MRI) |
Dr Fulvio Zaccagna |
31 Dec 2018 |
18 May 2017 |
Brain and CNS |
|
MyeChild 01 |
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy |
Dr Michael Gattens |
1 Nov 2021 |
31 Oct 2016 |
Haematological |
|
Myeloma XII (ACCoRd trial) Version 1.0 |
A phase III study to determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem |
Dr Charles Crawley |
31 Dec 2021 |
22 May 2017 |
Haematological |
|
National Lung Matrix Trial |
Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer |
Dr David Gilligan |
31 Jul 2018 |
17 Nov 2015 |
Lung |
|
NATT |
interNational Anaplastic Thyroid Cancer Tissue Bank and Database Project |
Dr Sarah Jefferies |
20 Nov 2018 |
20 Nov 2013 |
Head & neck |
|
NCRN - 2352 PiSARRO |
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 |
Dr Helena Earl |
31 Dec 2018 |
28 Feb 2014 |
Gynaecological |
|
NCRN525 (AZACITIDINE + BSC v PLACEBO + BSC) / AZA-MDS-003 |
A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromes |
Dr Theodora Foukaneli |
30 Oct 2020 |
27 Oct 2014 |
Haematological |
|
Neo-AEGIS |
Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (MAGIC regimen) vs. neoadjuvant chemoradiation (CROSS protocol) in adenocarcinoma of the oesophagus and oesophago-gastric junction |
Dr Hugo Ford |
1 Sep 2020 |
24 Nov 2015 |
Oesophageal |
|
Neo-RT |
Pre-operative breast intensity modulated radiotherapy in patients receiving neo-adjuvant hormonal treatment for breast cancer – a feasibility study |
Dr Charlotte Coles |
1 Sep 2024 |
4 Dec 2017 |
Breast |
|
NIMRAD |
A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemotherapy or cetuximab |
Dr Gill Barnett |
6 Nov 2018 |
24 Oct 2014 |
Head & neck |
|
Non-Hodgkin Lymphoma in Young Adults |
A prospective UK population based study of incidence, treatment and outcomes |
Dr Ben Uttenthal |
31 Dec 2018 |
27 Oct 2016 |
Haematological |
|
Olympia / MA.36 |
A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy |
Dr Jean Abraham |
23 Jan 2019 |
23 Jan 2015 |
Breast |
|
OPTIMA |
Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis |
Dr Luke Hughes-Davies |
31 Oct 2020 |
25 Oct 2012 |
Breast |
|
PanCO (ONCOSIL) |
An open label, single arm safety study of OncoSil™, administered to study participants with unresectable locally advanced pancreatic adenocarcinoma, given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel chemotherapies |
Dr Thankamma Ajithkumar |
1 Jan 2019 |
24 Oct 2017 |
Pancreatic |
|
PARADIGM OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa: |
Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study |
Dr Sarah Jefferies |
31 Dec 2018 |
4 Nov 2016 |
Brain and CNS |
|
PARTNER |
Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA |
Dr Jean Abraham |
31 Mar 2021 |
12 May 2016 |
Breast |
|
PATHOS |
A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer |
Dr Ekpemi Irune |
28 Feb 2019 |
16 Jun 2017 |
Head & neck |
|
PIVOTALboost |
A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost. |
Dr Yvonne Rimmer |
31 Dec 2021 |
7 Mar 2018 |
Prostate |
|
plasmaMATCH |
A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening |
Dr Richard Baird |
31 Dec 2018 |
11 Apr 2017 |
Breast |
|
PLATO |
PersonaLising Anal cancer radioTherapy dOse |
Dr Catherine Jephcott |
31 Dec 2022 |
22 Mar 2017 |
Colorectal |
|
POPS |
A randomised phase II trial assessing Post-Operative use of ProSpare, a rectal obturator in prostate cancer radiotherapy |
Dr Yvonne Rimmer |
31 Dec 2019 |
4 Jul 2017 |
Prostate |
|
POSNOC |
POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy. A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes |
Professor John Benson |
30 Sep 2018 |
8 Aug 2014 |
Breast |
|
PRaM-GBM |
Predicting sites of tumour progression in the invasive margin of glioblastomas |
Mr Stephen Price |
31 Oct 2018 |
1 Feb 2017 |
Brain and CNS |
|
PRIMETIME |
Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers |
Dr Charlotte Coles |
31 Dec 2021 |
18 May 2017 |
Breast |
|
ProCAID |
An open label phase I/randomised, double-blind phase II study in metastatic castration resistant Prostate Cancer of AZD5363 in combination with Docetaxel and prednisolone chemotherapy |
Dr Danish Mazhar |
30 Apr 2018 |
14 Nov 2017 |
Prostate |
|
PROMISE-meso |
A multicentre randomised phase III trial comparing pembrolizumab versus standard chemotherapy for advanced pre-treated malignant pleural mesothelioma |
Dr David Gilligan |
31 Dec 2018 |
27 Nov 2017 |
Lung |
|
ProT4 (Prophylactic Transfer of CD4 Lymphocytes) |
Multicentre randomised phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for haematological cancers |
Dr Ben Uttenthall |
8 Nov 2018 |
25 Jan 2013 |
Haematological |
|
PUrE |
The clinical and cost effectiveness of surgical interventions for stones in the lower kidney: The PUrE RCTPercutaneous Nephrolithotomy (PNL), Flexible Ureterorenoscopy (FURS) and Extracorporeal Lithotripsy (ESWL) for lower pole Kidney stones |
Dr Oliver Wiseman |
1 Dec 2020 |
15 Jul 2016 |
Kidney |
|
Quartus |
Quantification of breast radiotheraphy associated in late toxicity using novel ultrasound techniques |
Dr Charlotte Coles |
31 Jan 2019 |
13 May 2016 |
Breast |
|
RAIDER |
A Randomised phase II trial of Adaptive Image guided standard or Dose Escalated tumour boost Radiotherapy in the treatment of transitional cell carcinoma of the bladder |
Dr Yvonne Rimmer |
21 Mar 2029 |
6 Jan 2016 |
Bladder |
|
RAPPER |
Radiogenomics: assessment of polymorphisms for predicting the effects of radiotherapy |
Dr Gill Barnett |
31 Jul 2018 |
11 Jan 2006 |
Bladder, Brain and CNS, Head & neck, Prostate, Sarcoma |
|
Rational MCC |
Rational treatment selection for Merkel Cell Carcinoma (MCC): A randomised phase III multi-centre trial comparing radical surgery and radical radiotherapy as first definitive treatment for primary MCC with an observational study for patients ineligible for the randomised trial. |
Dr Kate Fife |
31 Dec 2022 |
22 Dec 2016 |
Skin & melanoma |
|
rEECur |
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma |
Dr Denise Williams |
30 Apr 2020 |
5 May 2016 |
Sarcoma |
|
RENA 4970 (The Water Study) |
Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue |
Mr Tevita Aho |
30 Nov 2019 |
4 Feb 2016 |
Prostate |
|
ROAM |
Radiation versus observation following surgical resection of atypical meningioma: A randomised controlled trial |
Dr Sarah Jefferies |
30 Apr 2025 |
17 Nov 2016 |
Brain and CNS |
|
SARON |
Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. A randomised phase III trial |
Dr Susan Harden |
4 Jul 2023 |
9 Aug 2017 |
Lung |
|
SCALOP-2 |
A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer |
Dr Thankamma Ajithkumar |
21 Mar 2019 |
18 Aug 2016 |
Pancreatic |
|
SCOPE-2 |
A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemoradiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET). |
Dr Susan Harden |
31 Dec 2025 |
28 Feb 2018 |
Oesophageal |
|
SelPac |
A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in Metastatic Uveal Melanoma |
Dr Pippa Corrie |
2 Mar 2019 |
1 Aug 2015 |
Skin & melanoma |
|
SMS Study |
Study of Somatic Sutations using genome Sequencing |
Dr Philip Jones |
1 Aug 2018 |
18 Oct 2015 |
Skin & melanoma |
|
SSGXXII |
Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study |
Dr Ramesh Bulusu |
31 Dec 2020 |
1 Mar 2017 |
Sarcoma |
|
Tamarin |
Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms |
Dr Anna Godfrey |
31 Jul 2018 |
14 Dec 2016 |
Haematological |
|
The Causes of Clonal Blood Cell Disorders |
The Causes of Clonal Blood Cell Disorders |
Professor Tony Green |
30 Apr 2018 |
6 Nov 2007 |
Haematological |
|
The MPN Experimental Assessment of Symptoms by Utilizing Repetitive Evaluation (MEASURES) |
Serial Assessment of Symptomatic Response to Non Experimental Medical Therapies and/or Phlebotomy in Patients with Myeloproliferative Neoplasms |
Dr Anna Godfrey |
31 Dec 2020 |
12 Jul 2017 |
Haematological |
|
True NTH UK Post Surgical Follow Up |
Development and evaluation of a patient reported instrument to monitor oncological and functional outcomes after radical prostatectomy |
Dr Nimish Shah |
31 May 2018 |
29 Apr 2016 |
Prostate |
|
UK Gastrointestinal Stromal Tumour (GIST) Registry |
To set up a specific GIST registry, which will enable incidence, prevalence, recurrence, survival and mortality rates, as well as treatment practices, to be monitored, thereby enabling therapeutic intervention to be evaluated and ultimately optimised. |
Professor Khrishna Chatterjee |
31 May 2021 |
9 Apr 2012 |
Sarcoma |
|
UK Haplo |
A UK multicentre phase II study of haploidentical stem cell transplantation in patients with haematological |
Dr Ben Uttenthal |
30 Jun 2018 |
28 Apr 2015 |
Haematological |
|
UK P3BEP Trial |
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours |
Dr Danish Mazhar |
30 Jun 2020 |
5 May 2017 |
Testicular |
|
UK Target CML Study |
Real world UK use of Tyrosine Kinase Inhibitors (TKIs): A Retrospective description of manaGement pathways, clinical responses and compliance with 2013 European LeukemiaNeT (ELN) recommendations for Chronic Myeloid Leukemia (CML) |
Dr Brian Huntley |
30 Jun 2020 |
12 Jan 2016 |
Haematological |
|
UKALL 14 |
A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia |
Dr Jenny Craig |
30 Jun 2018 |
31 Jul 2012 |
Haematological |
|
UKALL 2011 |
United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011 |
Dr Michael Gattens |
30 Apr 2019 |
19 Jun 2012 |
Haematological, Child & Leukaemia |
|
UTX-TGR-205 |
A phase 2b randomised study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated diffuse large B-cell lymphoma |
Dr Daniel Hodson |
30 Apr 2018 |
29 Dec 2017 |
Haematological |
|
VIT 09-10 |
International randomised phase II trial of the combinations of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in patients with refractory of relapsed rhabdomyosarcoma |
Dr Helen Hatcher |
30 Apr 2021 |
20 Jun 2013 |
Sarcoma |
|
VoxTox - CNS |
An observational study to collect comprehensive toxicity data for patients undergoing image-guided intensity-modulated radiotherapy to the head and neck, prostate, and central nervous system |
Dr Raj Jenna |
9 Jan 2023 |
27 Feb 2013 |
Brain and CNS |
|
VoxTox Head and Neck |
An observational study to collect comprehensive toxicity data for patients undergoing image-guided intensity-modulated radiotherapy to the head and neck, prostate, and central nervous system |
Dr Raj Jena |
9 Jan 2023 |
27 Feb 2013 |
Head & neck |
